Efficacy of solifenacin on irritable bowel syndrome with diarrhea: Open-label prospective pilot trial

Journal of Neurogastroenterology and Motility

Volumn 18, Issue 3, 2012, Pages 317-323

  Fukushima, Yasushi ^a   Suzuki, Hidekazu ^b   Matsuzaki, Juntaro ^b   Kiyosue, Arihiro ^a   Hibi, Toshifumi ^b  

^a Tokyo Eki Center Building Clinic   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diarrhea; Overactive; Ramosetron; Solifenacin succinate; Urinary bladder

Indexed keywords

RAMOSETRON; SOLIFENACIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY SCALE; IRRITABLE COLON; LOOSE FECES; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; XEROSTOMIA;

EID: 84872872762     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2012.18.3.317     Document Type: Article

References (13)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
2. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999;13: 371-384.
3. Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria. Patient Prefer Adherence 2008;2: 143-147.
4. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-235.
5. Chiba T, Kudara N, Sato M, et al. Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil. Hepatogastroenterology 2005; 52:1416-1420.
6. McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 2010;22:1029-1035, e1268.
7. Lindqvist S, Hernon J, Sharp P, et al. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol 2002;137:1134-1142.
8. Peretto I, Petrillo P, Imbimbo BP. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev 2009; 29:867-902.
9. Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Jpn J Pharmacol 2001; 86:281-288.
10. Matsuzaki J, Suzuki H, Fukushima Y, et al. High frequency of overlap between functional dyspepsia and overactive bladder. Neurogastroenterol Motil Published Online First: 23 May 2012. doi: 10.1111/ j.1365-2982.2012.01939.x.
11. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43: 1202-1211.
12. Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007;19:630-637.
13. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008;103:1229-1239.